Company Overview and News

Sandstorm Gold: It Will Pay Off To Be Patient

2018-05-16 seekingalpha
Sandstorm gold posted record revenue of $19.5 million for the three months ended March 31, 2018, compared with $18.8 million for the comparable period in 2017.

Teranga Gold - I'm Still Bullish

2018-05-16 seekingalpha
In my opinion, the company is heading in the right direction: Sabodala performs well and the Wahgnion gold project in Burkina Faso is entering the development stage.

Sandstorm Gold's (SAND) CEO Nolan Watson on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good morning. My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sandstorm Gold conference call. All lines have been placed on mute to prevent any background noise.

Hummingbird Resources Sets Ambitious Goals

2018-05-10 seekingalpha
Hummingbird Resources (OTCPK:HUMRF) has come a very long way since I covered the company in SA in November 2017. It poured first gold at its Yanfolila gold mine in Mali at the end of December 2017, and it achieved commercial production as of 1 April 2018. What’s remarkable in this case is that the project was delivered on time and on budget, which is pretty rare in the gold mining space.

This Billionaire Has Put Half His Net Worth Into Gold - Bloomberg

2018-05-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Endeavour to Announce its Q1 Results and Host Webcast on May 15th 2018

2018-04-27 globenewswire
George Town, April 27th, 2018 - Endeavour Mining (TSX:EDV) (OTCQX:EDVMF) provides notice that it will release its financial results for the first quarter of 2018 on Tuesday, May 15th, before TSX market open. Management invites you to participate in a conference call and live webcast on the same day at 8:30am (EST) to discuss the Company's financial and operational results.

5 Gold Stocks With Recent Insider Buying

2018-03-27 seekingalpha
I see insider buying as mostly a positive sign; it implies that insiders are bullish on company stock and think the price will rise.

Endeavour Mining Corporation 2017 Q4 - Results - Earnings Call Slides

2018-03-14 seekingalpha
The following slide deck was published by Endeavour Mining Corporation in conjunction with their 2017 Q4 earnings call.

Teranga Gold - I Am Optimistic In The Medium Term

2018-03-07 seekingalpha
In the medium term Teranga share prices should be supported by the company's largest shareholder; since November 2017 this shareholder has purchased 2.05 million shares and is still buying.

Sandstorm Gold's (SAND) CEO Nolan Watson on Q4 2017 Results - Earnings Call Transcript

2018-02-17 seekingalpha
Good morning. My name is Leonie and I'll be your conference operator today. At this time, I would like to welcome everyone to the Sandstorm Gold Fourth Quarter Results Conference Call. [Operator Instructions] Please be aware that some of the commentary may contain forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.

After years of protest, I. Coast locals ink deal with... | Daily Mail Online

Since it first began production in 2014, Agbaou gold mine in central Ivory Coast has been hit by protests

Endeavour in talks to avert Ivory Coast protests over gold production plans

2018-02-09 reuters
ABIDJAN, Feb 9 (Reuters) - Endeavour Mining has opened negotiations with local people in Ivory Coast in an effort to head off protests at two gold mines where the company aims to boost production by nearly 4 percent this year, its country manager said on Friday.

Resource Sector Digest: Pretium Coming Undone?

2018-02-01 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: G3040R109